Chemical biology & drug designHumansCarcinomaNon-Small-Cell LungLung NeoplasmsAntibodies
Molecular Mechanisms and Efficacy of Tislelizumab, a PD-1 Inhibitor Developed in China, in Non-Small Cell Lung Cancer.
Yihao Liu, Wenjun Meng, Lu Pan, Haoling Zhang, Qinqin He
Published: 202610.1111/cbdd.70252
Abstract
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. Tislelizumab, a PD-1 inhibitor developed in China, has shown promisi…
Preview only. Read the full abstract at the source